Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study (Q82777810)
Jump to navigation
Jump to search
scientific article published on 01 April 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study |
scientific article published on 01 April 2010 |
Statements
Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study (English)
Joel Kremer
Christopher Ritchlin
Alan Mendelsohn
Daniel Baker
Lilianne Kim
Zhenhua Xu
John Han